Nuveen Asset Management LLC lessened its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 32.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 153,077 shares of the company's stock after selling 74,087 shares during the period. Nuveen Asset Management LLC owned about 0.29% of Zevra Therapeutics worth $1,277,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in ZVRA. BNP Paribas Financial Markets bought a new stake in Zevra Therapeutics during the 4th quarter worth approximately $53,000. Invesco Ltd. raised its stake in Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after acquiring an additional 3,007 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Zevra Therapeutics by 51.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock worth $172,000 after acquiring an additional 6,966 shares during the period. SG Americas Securities LLC raised its stake in Zevra Therapeutics by 54.6% during the 4th quarter. SG Americas Securities LLC now owns 23,500 shares of the company's stock worth $196,000 after acquiring an additional 8,302 shares during the period. Finally, D. E. Shaw & Co. Inc. bought a new stake in Zevra Therapeutics during the 4th quarter worth approximately $209,000. Institutional investors own 35.03% of the company's stock.
Zevra Therapeutics Price Performance
Shares of NASDAQ ZVRA traded down $0.12 during mid-day trading on Thursday, hitting $8.83. 499,201 shares of the company's stock traded hands, compared to its average volume of 652,253. The company's 50-day moving average is $7.72 and its two-hundred day moving average is $8.08. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company has a market capitalization of $482.82 million, a P/E ratio of -4.48 and a beta of 2.01. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. The firm had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the prior year, the company earned ($0.40) EPS. On average, equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.
Insider Activity
In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of the firm's stock in a transaction dated Wednesday, March 19th. The shares were purchased at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the transaction, the director now owns 40,000 shares of the company's stock, valued at $318,400. This represents a 33.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.40% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Guggenheim increased their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Canaccord Genuity Group increased their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Finally, JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $22.29.
Read Our Latest Stock Analysis on ZVRA
Zevra Therapeutics Company Profile
(
Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Featured Articles
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
